Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Larry N Feinberg, Oracle Associates Open Activist Position in BIOLASE

Larry N Feinberg, the manager of Oracle Associates, has opened a position in BIOLASE Inc (NASDAQ:BIOL). In a recent filing with the Securities and Exchange Commission, Mr. Feinberg disclosed ownership of 3,447,331 shares, which correspond to 9.89% of the company’s common stock.


BIOLASE engages in the production and sale of lasers used in medicinal practice. The stock price had been in an uptrend since the start of the year, advancing by 230% to an April high of $5.9 per share. The price has been trending down ever since, with shares currently traded at $1.8 apiece. BIOLASE has a market cap of $144 million and the stock has a beta of 2.55, which makes it a fairly volatile one. The company does not pay a dividend.

The drop in share price was not unwarranted. BIOLASE has registered poor financial results in the third quarter of 2013. The company reported revenues of $12.3 million, down from $13.8 million for the same period of 2012. The loss per share increased from $0.02 reported for Q3 of 2012 to $0.13 per share during the last quarter.

On November 11, BIOLASE announced that its board of directors has allowed the company to hire an investment bank in order to explore the possibility of a merger or acquisition. Federico Pignatelli, Chairman and CEO of BIOLASE, said:

The Company is currently valued at approximately one-times revenue, and we believe that certain of its assets could be worth significantly more.

BIOLASE has already begun the process of interviewing and evaluating several investment banks and is committed to conducting a review of potential opportunities as promptly as practicable; however, there can be no assurance that any particular opportunity will be pursued or that any transaction will occur, or on what terms or as to the timing.

Disclosure: none

Recommended reading:

Edward A. Mule, Silver Point Capital Increase Position in Cooper-Standard Holdings

Hedge Fund News: Stanley Druckenmiller, Carl Icahn & Christopher Hansen

Mohnish Pabrai, Dalal Street Keep Buying Horshead Holding Corp Shares

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!